TCGA-KQ-A41R-01A-21R-A352-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 44.34954008
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.370
- SPERMATOGENESIS+0.260
- BILE_ACID_METABOLISM+0.200
- COAGULATION+0.200
- PANCREAS_BETA_CELLS+0.190
- XENOBIOTIC_METABOLISM+0.120
- MYOGENESIS+0.090
- APICAL_SURFACE+0.010
- ESTROGEN_RESPONSE_LATE-0.020
- ANGIOGENESIS-0.030
Top 10 suppressed
- PROTEIN_SECRETION-0.630
- TGF_BETA_SIGNALING-0.580
- MYC_TARGETS_V1-0.550
- MITOTIC_SPINDLE-0.520
- G2M_CHECKPOINT-0.510
- MTORC1_SIGNALING-0.500
- E2F_TARGETS-0.490
- PI3K_AKT_MTOR_SIGNALING-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.460
- ANDROGEN_RESPONSE-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A8HX-01A-11R-A36F-07 | — | — | 0.943 |
| 2 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.934 |
| 3 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.927 |
| 4 | MNG339 | — | — | 0.925 |
| 5 | MNG1044 | — | — | 0.924 |
| 6 | SRR1400997 | GTEX | — | 0.924 |
| 7 | TCGA-KQ-A41N-01A-11R-A33J-07 | — | — | 0.921 |
| 8 | SRR1490465 | GTEX | — | 0.921 |
| 9 | MDT-AP-0706 | Med | Medulloblastoma | 0.920 |
| 10 | TCGA-E7-A8O8-01A-11R-A36F-07 | — | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |